All children | Pediatric characteristics by year of enrolment | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
All years | 2005-2007 | 2008-2009 | 2010-2011 | p value for trend | ||||||
N = 4,699 | N = 1,229 | N = 1,877 | N = 1,593 | |||||||
n | (%) | n | (%) | n | (%) | n | (%) | |||
Gender | Female | 2479 | (52.8) | 674 | (54.8) | 984 | (52.4) | 821 | (51.5) | 0.09 |
Male | 2220 | (47.2) | 555 | (45.2) | 893 | (47.6) | 772 | (48.5) | ||
Age at enrolment (years) | 0-1 years | 1219 | (25.9) | 227 | (18.5) | 491 | (26.1) | 501 | (31.5) | <0.0001 |
2-4 years | 1162 | (24.7) | 280 | (22.8) | 479 | (25.5) | 403 | (25.3) | ||
5-9 years | 1431 | (30.5) | 413 | (33.6) | 586 | (31.2) | 432 | (27.1) | ||
10-14 years | 887 | (18.9) | 309 | (25.1) | 321 | (17.1) | 257 | (16.1) | ||
Point of entry into HIV care | Point of entry documented | 4294 | (91.4) | 1066 | (86.7) | 1757 | (93.6) | 1471 | (92.3) | <0.0001 |
VCT | 1908 | (44.4) | 356 | (33.4) | 867 | (49.3) | 685 | (46.6) | <0.0001 | |
PMTCT | 483 | (11.2) | 75 | (7.0) | 188 | (10.7) | 220 | (15.0) | ||
Other 1 | 1903 | (44.3) | 635 | (59.6) | 702 | (40.0) | 566 | (38.5) | ||
Transferred in | Yes | 506 | (10.8) | 54 | (4.4) | 249 | (13.3) | 203 | (12.7) | <0.0001 |
WHO stage at enrolment | WHO stage documented | 4017 | (85.5) | 816 | (66.4) | 1695 | (90.3) | 1506 | (94.5) | <0.0001 |
I | 836 | (20.8) | 110 | (13.5) | 351 | (20.7) | 375 | (24.9) | <0.0001 | |
II | 1183 | (29.4) | 189 | (23.1) | 477 | (28.1) | 517 | (34.3) | ||
III | 1291 | (32.1) | 330 | (40.4) | 557 | (32.9) | 404 | (26.8) | ||
IV | 707 | (17.6) | 187 | (22.9) | 310 | (18.3) | 210 | (13.9) | ||
ART eligibility at enrolment2 | Eligible | 1936 | (41.2) | 468 | (38.1) | 810 | (43.2) | 658 | (41.3) | <0.0001 |
Not eligible | 1447 | (30.8) | 284 | (23.1) | 607 | (32.3) | 556 | (34.9) | ||
Unknown eligibility | 1316 | (28.0) | 477 | (38.8) | 460 | (24.5) | 379 | (23.8) | ||
Started ART | Yes | 2599 | (55.3) | 742 | (60.4) | 1045 | (55.7) | 812 | (51.0) | <0.0001 |
Age at ART initiation (years) | 0-1 years | 690 | (26.5) | 108 | (14.6) | 270 | (25.8) | 312 | (38.4) | <0.0001 |
2-4 years | 576 | (22.2) | 150 | (20.2) | 249 | (23.8) | 177 | (21.8) | ||
5-9 years | 799 | (30.7) | 266 | (35.8) | 338 | (32.3) | 195 | (24.0) | ||
10-14 years | 534 | (20.5) | 218 | (29.4) | 188 | (18.0) | 128 | (15.8) | ||
First ART regimen3 | Stavudine containing | 920 | (35.4) | 295 | (39.8) | 413 | (39.5) | 212 | (26.1) | <0.0001 |
Zidovudine containing | 1636 | (62.9) | 440 | (59.3) | 623 | (59.6) | 573 | (70.6) | ||
Other4 | 43 | (1.7) | 7 | (0.9) | 9 | (0.9) | 27 | (3.3) | ||
CD4+ at enrolment5 | Number of children ≥5y | 2318 | - | 722 | - | 907 | - | 689 | - | |
(cells/μL), children ≥5 years | CD4+ documented | 941 | (40.6) | 282 | (39.1) | 364 | (40.1) | 295 | (42.8) | 0.15 |
<50 | 112 | (11.9) | 35 | (12.4) | 43 | (11.8) | 34 | (11.5) | 0.06 | |
50-99 | 50 | (5.3) | 23 | (8.2) | 11 | (3.0) | 16 | (5.4) | ||
100-199 | 111 | (11.8) | 39 | (13.8) | 48 | (13.2) | 24 | (8.1) | ||
200-349 | 134 | (14.2) | 39 | (13.8) | 53 | (14.6) | 42 | (14.2) | ||
≥350 | 534 | (56.7) | 146 | (51.8) | 209 | (57.4) | 179 | (60.7) | ||
CD4+ at ART initiation5, (cells/μL), children ≥5 years | CD4+ documented | 660 | (28.5) | 219 | (30.3) | 276 | (30.4) | 165 | (23.9) | 0.007 |
<50 | 111 | (16.8) | 37 | (16.9) | 40 | (14.5) | 34 | (20.6) | 0.28 | |
50-99 | 68 | (10.3) | 28 | (12.8) | 24 | (8.7) | 16 | (9.7) | ||
100-199 | 138 | (20.9) | 43 | (19.6) | 67 | (24.3) | 28 | (17.0) | ||
200-349 | 149 | (22.6) | 55 | (25.1) | 58 | (21.0) | 36 | (21.8) | ||
≥350 | 194 | (29.4) | 56 | (25.6) | 87 | (31.5) | 51 | (30.9) |